About Likarda
Likarda is a company based in Kansas City (United States) founded in 2012. Likarda has raised $4 million across 2 funding rounds from investors including HHS. The company has 8 employees as of December 31, 2022. Likarda offers products and services including Core-Shell Spherification, Microencapsulation, and ViscoBeads. Likarda operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Kansas City, United States
- Employees 8 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Likarda, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$4 M (USD)
in 2 rounds
-
Latest Funding Round
$256.34 K (USD), Grant
Sep 07, 2021
- Investors
-
Employee Count
8
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Likarda
Likarda offers a comprehensive portfolio of products and services, including Core-Shell Spherification, Microencapsulation, and ViscoBeads.
Method for encapsulating cells to optimize therapy delivery and efficacy.
Process to protect cell therapies from immune systems using hydrogels.
Customizable beads for targeted cell therapy administration.
People of Likarda
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Likarda
Likarda has successfully raised a total of $4M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $256.34 thousand completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $256,338
-
First Round
First Round
(28 Aug 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2021 | Amount | Grant - Likarda | Valuation |
investors |
|
| Aug, 2017 | Amount | Series A - Likarda | Valuation |
investors |
|
Investors in Likarda
Investments & Acquisitions by Likarda
Financial Statements - Likarda
Likarda Comparisons
Competitors of Likarda
Likarda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Frequently Asked Questions about Likarda
Likarda was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Likarda is headquartered in Kansas City, United States. It is registered at Kansas City, Missouri, United States.
Likarda is a funded company, having raised a total of $4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4M, raised on Aug 28, 2017.
As of Dec 31, 2022, the latest employee count at Likarda is 8.
Likarda is creating 3D cell culturesminiaturized organs from their proprietary cell culture systems which will have potential applications in drug discovery, development, cell-based transplantation, and regenerative medicine. The company offers integrated early-stage discovery research along with consultative and analytical services. The company has created Kanslet, a reaggregated islet capable of producing insulin (from a donor pancreas) which can be transplanted into dogs and cats for treating diabetes. Kanslets can also be used for secondary drug testing and multiple studies have been published already in support of the technology.
Likarda's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Likarda offers Core-Shell Spherification, Microencapsulation, and ViscoBeads.
Likarda has 1 investor. Key investors include HHS.